EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY-NC-ND 4.0

Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: a retrospective case-control study

Yi Luan, Jie Wei, Ke Wang, Donghao Cai, Xiaohong Luo, Wanhung Fan, Haijiang Wang, Chaohui Duan

Journal of Bio-X Research · 2021-06 · 04 (02) · 60-66

DOI: 10.1097/jbr.0000000000000093 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Journal of Bio-X Research, online erschienen am 25.06.2021. Verfasst von Yi Luan und 7 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Serum tumor markers are seldom considered as diagnostic biomarkers for breast cancer because they lack good sensitivity or specificity. This study aimed to evaluate whether a combination of circulating tumor cells (CTCs) and the serum tumor markers carcinoembryonic antigen (CEA), cancer antigen (CA)125, and CA15-3 might improve their diagnostic performance.

Methods

We performed a retrospective case-control study of patients with breast cancer or benign breast diseases (BBD) and healthy female donors (HDs) who underwent preoperative CTC detection and serum tumor marker tests between December 2017 and November 2018. CTC detection and serum tumor marker test results were collected from 177 breast cancer patients, 64 patients with BBD, and 20 HDs. Correlations between CTC, CEA, CA125, or CA15-3 and participants’ clinical characteristics were then analyzed. The diagnostic performances of CTC, CEA, CA125, and CA15-3 were estimated using the area under the receiver operating characteristic curve (AUC). This study was approved by the Institutional Review Board of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, China (approval No. [2018] kuaishendi(75)) on May 24, 2018.

Results

CTC, CEA, and CA15-3 were able to distinguish breast cancer patients from controls (BBD+HDs) ( P

Zitieren

APA

Luan, Y., Wei, J., Wang, K., Cai, D., Luo, X., Fan, W., Wang, H., & Duan, C. (2021). Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: a retrospective case-control study. Journal of Bio-X Research, 04(02), 60-66. https://doi.org/10.1097/jbr.0000000000000093

Vancouver

Luan Y, Wei J, Wang K, Cai D, Luo X, Fan W, et al. Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: a retrospective case-control study. Journal of Bio-X Research. 2021;04(02):60-66. doi:10.1097/jbr.0000000000000093

BibTeX
@article{Luan2021,
  author = {Luan, Yi and Wei, Jie and Wang, Ke and Cai, Donghao and Luo, Xiaohong and Fan, Wanhung and Wang, Haijiang and Duan, Chaohui},
  title = {Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: a retrospective case-control study},
  journal = {Journal of Bio-X Research},
  year = {2021},
  volume = {04},
  number = {02},
  pages = {60--66},
  doi = {10.1097/jbr.0000000000000093}
}
Kostenlos starten →